Higher CDC20 expression has been observed in GBM compared with low‐grade gliomas, with patients with higher‐CDC20‐expressing GBM of the proneural subtype exhibiting significantly shorter overall survival [25]. The gene discussed is CDC20; the disease is central nervous system cancer.